Jorge Lima: Amniotic Fluid Embolism and Its Impact on Maternal and Perinatal Outcomes
Jorge Lima, Assistant Guest Professor at NOVA Medical School, Gynecologist and Obstetrician at Hospital da Luz Lisbon, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Obstetrical and Gynecological Survey, adding:
“I am pleased to share our latest article:
‘Amniotic Fluid Embolism: A Silent Threat to Maternal Life—An Up-to-Date Comprehensive Review of the Pathophysiology, Diagnosis, and Outcome.’
Published in Obstetrical and Gynecological Survey, one of the leading review journals in Obstetrics and Gynecology, this article provides an up-to-date overview of amniotic fluid embolism (AFE), one of the most devastating and unpredictable obstetric emergencies.
Together with Oluwateniayo O. Okpaise, João Feldman de Pinho, Edna Kathleen Porter, and Rodrigo Ruano, we review current evidence on:
- Epidemiology and risk factors;
- Pathophysiological and immunological mechanisms;
- Diagnostic challenges and emerging biomarkers;
- Contemporary management strategies;
- Maternal and neonatal outcomes.
Although rare, AFE remains associated with substantial maternal and perinatal morbidity and mortality.
Improving awareness, facilitating early diagnosis, and optimizing multidisciplinary management are essential to improving outcomes.
I am grateful to my co-authors for this rewarding international collaboration (UK ,USA and Portugal) and for their commitment to advancing knowledge in maternal-fetal medicine.”
Title: Amniotic Fluid Embolism: A Silent Threat to Maternal Life— An Up-to-Date Comprehensive Review of the Pathophysiology, Diagnosis, and Outcome
Authors: Oluwateniayo O. Okpaise, Jorge Lima, João Feldman de Pinho, Edna Porter Kathleen, Rodrigo Ruano

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 11, 2026, 15:42Tareq Abadl: The Clinical Impact of Kell Alloimmunization
-
Nov 11, 2026, 15:30Alejandro González Veliz: Does PCI Change The Long-Term Outcome In Stable Coronary Artery Disease?
-
Nov 11, 2026, 15:25Preparing for the SoHO Regulation – EBA Board Convenes in Vienna – European Blood Alliance
-
Nov 11, 2026, 15:20Vaidehi Prasanth: IV Iron in Heart Failure – Exploring Hospitalisation Benefits vs. Infection Risk in Open Heart
-
Nov 11, 2026, 15:18Stefan Prendić: Can Algorithms Support Antibody Identification in Immunohematology?
-
Nov 11, 2026, 15:12Perioperative Challenges in Hemophilia Patients on Rebalancing Therapies
-
Nov 11, 2026, 15:03Maria Elisa Mancuso: World-Renowned Faculty and 33 Global Participants Unite at Hemophilia Academy 2026
-
Nov 11, 2026, 15:01Hassan Raza: The JAK2 V617F Revolution
-
Nov 11, 2026, 14:57Edward Lee Carter: Factor Xla Inhibition Enters Clinical Practice – FDA Approval of Asundexian